PR95917

TAIPEI,May10,2022/PRNewswire=KYODO JBN/--

Bora establishes a leadership position in Taiwan's CDMO sector as it continues

to expand into the global CDMO market

Taiwan-based premier international contract development and manufacturing

organization (CDMO) Bora Pharmaceuticals recently announced the establishment

of Bora Biologics Co., Ltd., a CDMO platform for biologics. Besides Bora,

investors into the new entity include Taishin Healthcare Limited Partnership

and Tanvex BioPharma founder Dr. Allen Chao. Bora also announced that they will

initially invest $50 million USD and up to $100 million USD in the acquisition

of Eden Biologics' CDMO assets in Taiwan as part of its 5-year growth plan.

With Bora's strengths as a CDMO for small molecules and biological

macromolecules, the company has established a leadership position in Taiwan

with its comprehensive CDMO customer services and competitive market share.

In line with its strategy of building comprehensive CDMO capabilities, Bora

expands into biologic macromolecules and cell and gene therapy markets

Bora indicated that the strategic acquisition of Eden Biologics CDMO assets,

located in Hsinchu Biomedical Science Park, Taiwan,  will help Bora Group

rapidly build a presence in the biological macromolecules and cell and gene

therapy markets, and position the organization to expand its service offering

to their clients supporting new and innovative drug development.

Bora chairman Bobby Sheng explained that the acquisition of Eden Biologic's

CDMO assets is an important milestone as Bora continues to expand its presence

in the CDMO market. Bora has always been committed to the creation of a global

CDMO with comprehensive capabilities. The strategic cooperation with Taishin

Healthcare Limited Partnership and Dr. Allen Chao is in line with the firm's

long-term investment strategy for growth.

Expanding production capacity with international standards-based manufacturing

processes and technologies

With the acquisition of the facility, Bora will have biopharmaceutical

technologies related to the development of cell lines for the production of

protein drugs, the development and analysis of upstream and downstream

processes, along with the establishment of quality control and inspection

specifications, as well as cell bank generation.

"The addition of the CDMO facilities state of the art equipment and the

expertise of the highly qualified team gives Bora Biologics the ability to

develop and continue with our clients as they progress to commercialization."

Bora Vice President Simon Chen said.

Mr. Chen further explained that the facility has four 500L bioreactors, all of

which have been certified by the EU Qualified Person (QP) and the Taiwan Food

and Drug Administration, Ministry of Health and Welfare. The facility has

proven its comprehensive CDMO capabilities by having completed several

collaborative projects with many international partners.

Bora Pharmaceuticals is a premier international CDMO specializing in a wide

range of complex dosage forms including oral solid, liquid, and semi-solid

capabilities for both Rx and OTC products, as well as, macromolecule

biologics.  Bora owns and operates multiple cGMP manufacturing facilities in

Asia and North America offering services for clinical and commercial

manufacturing, packaging, and analytical testing.  For more information

contact: info@bora-corp.com

SOURCE:  Bora corp

Image Attachments Links:

   Link: http://asianetnews.net/view-attachment?attach-id=420864

   Caption: Eden Biologics CDMO assets, located in Hsinchu Biomedical Science Park, Taiwan